新型脓毒症生物标志物Presepsin(sCD14-亚型)的研究进展

Research progress of presepsin:a newly identified soluble CD14 subtype as a marker for sepsis

脓毒症(sepsis)是宿主对感染的特异性反应失调导致的危及生命的器官功能损害,是重症监护病房(ICU)患者的主要死亡原因。生物标志物在早期识别诊断脓毒症、病情评价、指导抗生素应用及预后评估方面具有重要意义。不同于降钙素原(PCT)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)等炎症标志物,近来发现的一种新型生物标志物可溶性CD14亚型(Presepsin)在脓毒症的诊断及评价中显示了良好的临床意义,具有良好的临床应用前景。

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which is the leading cause of death in critically ill patients in intensive care unit （ICU）. Circulating bio-markers are helpful in early diagnosis of sepsis, evaluating the severity, guiding antimicrobials management and predicting outcomes. Unlike procalcitonin, interleukin-6 or C-reactive protein, an newly discovered bio-marker ＂Presepsin＂ has been shown as a useful effect on early diagnosis and accessment of sepsis, which will become to be a prospective clinical application.